Both in Pharmaceuticals
Keros Therapeutics vs Upstream Bio
Over the past year KROS returned −30.4% and UPB returned −85.2%; their daily moves had a correlation of 0.28.
KROS −30.4% UPB −85.2%Growth of $1, one year, split-adjusted
| Metric | KROS | UPB |
|---|---|---|
| Price | $10.83 | $3.70 |
| Market cap | $214.7M | $202.7M |
| Today | 0.00% | +9.14% |
| 1 month | −1.6% | −19.4% |
| 6 months | −8.1% | −59.7% |
| Year to date | −46.8% | −86.4% |
| 1 year | −28.8% | −85.2% |
| Revenue growth (YoY) | −100.0% | −17.5% |
| Gross margin | — | 100.0% |
| Net margin | — | −5136.1% |
| P/E (TTM) | — | — |
| Price / sales | 14.3× | 64.2× |
| Net cash | $257.6M | $261.3M |
| Dividend yield | — | — |
| Volatility (60d) | 43.2% | 84.2% |
| Short % of float | 6.2% | 13.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).